

Ian McGowan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5492489/publications.pdf>

Version: 2024-02-01

138
papers

6,432
citations

87723

38
h-index

71532

76
g-index

141
all docs

141
docs citations

141
times ranked

5704
citing authors

#	ARTICLE	IF	CITATIONS
1	Tenofovir-Based Preexposure Prophylaxis for HIV Infection among African Women. <i>New England Journal of Medicine</i> , 2015, 372, 509-518.	13.9	1,094
2	Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women. <i>New England Journal of Medicine</i> , 2016, 375, 2121-2132.	13.9	624
3	Successes and challenges of HIV prevention in men who have sex with men. <i>Lancet, The</i> , 2012, 380, 388-399.	6.3	349
4	Phase I/II Trial of the Pharmacokinetics, Safety, and Antiretroviral Activity of Tenofovir Disoproxil Fumarate in Human Immunodeficiency Virus-Infected Adults. <i>Antimicrobial Agents and Chemotherapy</i> , 2001, 45, 2733-2739.	1.4	319
5	Prevention of SIV Rectal Transmission and Priming of T Cell Responses in Macaques after Local Pre-exposure Application of Tenofovir Gel. <i>PLoS Medicine</i> , 2008, 5, e157.	3.9	159
6	Enhanced levels of functional HIV-1 co-receptors on human mucosal T cells demonstrated using intestinal biopsy tissue. <i>Aids</i> , 2000, 14, 1761-1765.	1.0	153
7	Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF. <i>Aids</i> , 2002, 16, 1227-1235.	1.0	136
8	RMP-02/MTN-006: A Phase 1 Rectal Safety, Acceptability, Pharmacokinetic, and Pharmacodynamic Study of Tenofovir 1% Gel Compared with Oral Tenofovir Disoproxil Fumarate. <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 1412-1421.	0.5	129
9	Ex vivo culture of human colorectal tissue for the evaluation of candidate microbicides. <i>Aids</i> , 2006, 20, 1237-1245.	1.0	122
10	Lack of Decay of HIV-1 in Gut-Associated Lymphoid Tissue Reservoirs in Maximally Suppressed Individuals. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2006, 43, 65-68.	0.9	115
11	Binding and Transfer of Human Immunodeficiency Virus by DC-SIGN+ Cells in Human Rectal Mucosa. <i>Journal of Virology</i> , 2005, 79, 5762-5773.	1.5	108
12	Phase 1 randomized trial of the vaginal safety and acceptability of SPL7013 gel (VivaGel) in sexually active young women (MTN-004). <i>Aids</i> , 2011, 25, 1057-1064.	1.0	108
13	Increased HIV-1 Mucosal Replication Is Associated With Generalized Mucosal Cytokine Activation. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2004, 37, 1228-1236.	0.9	95
14	HIV and mucosal barrier interactions: consequences for transmission and pathogenesis. <i>Current Opinion in Immunology</i> , 2015, 36, 22-30.	2.4	95
15	A Phase 1 Randomized, Double Blind, Placebo Controlled Rectal Safety and Acceptability Study of Tenofovir 1% Gel (MTN-007). <i>PLoS ONE</i> , 2013, 8, e60147.	1.1	89
16	A Tunable, Biodegradable, Thin-Film Polymer Device as a Long-Acting Implant Delivering Tenofovir Alafenamide Fumarate for HIV Pre-exposure Prophylaxis. <i>Pharmaceutical Research</i> , 2016, 33, 1649-1656.	1.7	87
17	First Phase 1 Double-Blind, Placebo-Controlled, Randomized Rectal Microbicide Trial Using UC781 Gel with a Novel Index of Ex Vivo Efficacy. <i>PLoS ONE</i> , 2011, 6, e23243.	1.1	79
18	Reverse Transcriptase Inhibitors as Potential Colorectal Microbicides. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 1797-1807.	1.4	77

#	ARTICLE	IF	CITATIONS
19	Awareness of Post-Exposure Prophylaxis (PEP) and Pre-Exposure Prophylaxis (PrEP) Is Low but Interest Is High Among Men Engaging in Condomless Anal Sex With Men in Boston, Pittsburgh, and San Juan. <i>AIDS Education and Prevention</i> , 2015, 27, 289-297.	0.6	77
20	Long-acting rilpivirine as potential pre-exposure prophylaxis for HIV-1 prevention (the MWRI-01 study): an open-label, phase 1, compartmental, pharmacokinetic and pharmacodynamic assessment. <i>Lancet HIV</i> , 2016, 3, e569-e578.	2.1	77
21	Microbicides: A new frontier in HIV prevention. <i>Biologicals</i> , 2006, 34, 241-255.	0.5	72
22	Collaborative crafting in call centre teams. <i>Journal of Occupational and Organizational Psychology</i> , 2014, 87, 464-486.	2.6	70
23	Microbicides for HIV prevention: reality or hope?. <i>Current Opinion in Infectious Diseases</i> , 2010, 23, 26-31.	1.3	64
24	Rectal Microbicides: Can We Make Them and Will People Use Them?. <i>AIDS and Behavior</i> , 2011, 15, 66-71.	1.4	61
25	Extended Treatment With Tenofovir Disoproxil Fumarate in Treatment-Experienced HIV-1-Infected Patients: Genotypic, Phenotypic, and Rebound Analyses. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2003, 33, 15-21.	0.9	60
26	HIV-1 pathogenesis differs in rectosigmoid and tonsillar tissues infected ex vivo with CCR5- and CXCR4-tropic HIV-1. <i>Aids</i> , 2007, 21, 1263-1272.	1.0	60
27	Cytokine gene expression in HIV-infected intestinal mucosa. <i>Aids</i> , 1994, 8, 1569-1576.	1.0	56
28	Rectal Transmission of Transmitted/Founder HIV-1 Is Efficiently Prevented by Topical 1% Tenofovir in BLT Humanized Mice. <i>PLoS ONE</i> , 2013, 8, e60024.	1.1	54
29	HIV-related diarrhea is multifactorial and fat malabsorption is commonly present, independent of HAART. <i>American Journal of Gastroenterology</i> , 2001, 96, 1831-1837.	0.2	53
30	A Phase 1 Randomized, Open Label, Rectal Safety, Acceptability, Pharmacokinetic, and Pharmacodynamic Study of Three Formulations of Tenofovir 1% Gel (the CHARM-01 Study). <i>PLoS ONE</i> , 2015, 10, e0125363.	1.1	53
31	An aptamer that neutralizes R5 strains of HIV-1 binds to core residues of gp120 in the CCR5 binding site. <i>Virology</i> , 2008, 381, 46-54.	1.1	52
32	Characterization of Baseline Intestinal Mucosal Indices of Injury and Inflammation in Men for Use in Rectal Microbicide Trials (HIV Prevention Trials Network-056). <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2007, 46, 417-425.	0.9	45
33	Dose-Response Relationship Between Tissue Concentrations of UC781 and Explant Infectibility with HIV Type 1 in the RMP-01 Rectal Safety Study. <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 1422-1433.	0.5	44
34	The development of rectal microbicides for HIV prevention. <i>Expert Opinion on Drug Delivery</i> , 2014, 11, 69-82.	2.4	43
35	MTN-017: A Rectal Phase 2 Extended Safety and Acceptability Study of Tenofovir Reduced-Glycerin 1% Gel. <i>Clinical Infectious Diseases</i> , 2017, 64, ciw832.	2.9	42
36	Long-acting rilpivirine for HIV prevention. <i>Current Opinion in HIV and AIDS</i> , 2015, 10, 253-257.	1.5	41

#	ARTICLE	IF	CITATIONS
37	The human tissue-resident CCR5 ⁺ T cell compartment maintains protective and functional properties during inflammation. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	41
38	Palliative laser therapy for inoperable rectal cancer“does it work?. A prospective study of quality of life. <i>Cancer</i> , 1989, 63, 967-969.	2.0	40
39	“Tell Juliana” Acceptability of the Candidate Microbicide VivaGel® and Two Placebo Gels Among Ethnically Diverse, Sexually Active Young Women Participating in a Phase 1 Microbicide Study. <i>AIDS and Behavior</i> , 2012, 16, 1761-1774.	1.4	40
40	PHASE 2 STUDY OF THE SAFETY AND TOLERABILITY OF MARAVIROC-CONTAINING REGIMENS TO PREVENT HIV INFECTION IN MEN WHO HAVE SEX WITH MEN (MSM) (HPTN 069/ACTG A5305). <i>Journal of Infectious Diseases</i> , 2017, 215, jiw525.	1.9	40
41	Colorectal microbicide design. <i>Aids</i> , 2011, 25, 1971-1979.	1.0	39
42	Mucosal effects of tenofovir 1% gel. <i>ELife</i> , 2015, 4, .	2.8	37
43	Does peract ⁺ HIV ⁺ transmission risk through anal sex vary by gender? An updated systematic review and meta-analysis. <i>American Journal of Reproductive Immunology</i> , 2018, 80, e13039.	1.2	35
44	Acceptability of UC781 Gel as a Rectal Microbicide Among HIV-Uninfected Women and Men. <i>AIDS and Behavior</i> , 2010, 14, 618-628.	1.4	34
45	Rectal microbicides: a new focus for HIV prevention. <i>Sexually Transmitted Infections</i> , 2008, 84, 413-417.	0.8	33
46	Protection of HIV Neutralizing Aptamers against Rectal and Vaginal Nucleases. <i>Journal of Biological Chemistry</i> , 2011, 286, 2526-2535.	1.6	30
47	Variations in microbicide gel acceptability among young women in the USA and Puerto Rico. <i>Culture, Health and Sexuality</i> , 2012, 14, 151-166.	1.0	30
48	Heterosexual Anal Intercourse Has the Potential to Cause a Significant Loss of Power in Vaginal Microbicide Effectiveness Studies. <i>Sexually Transmitted Diseases</i> , 2010, 37, 361-364.	0.8	30
49	Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Women. <i>Annals of Internal Medicine</i> , 2017, 167, 384.	2.0	29
50	Correlation between Compartmental Tenofovir Concentrations and an Ex Vivo Rectal Biopsy Model of Tissue Infectibility in the RMP-02/MTN-006 Phase 1 Study. <i>PLoS ONE</i> , 2014, 9, e111507.	1.1	29
51	HHV8 DNA in normal gastrointestinal mucosa from HIV seropositive people. <i>Lancet, The</i> , 1996, 347, 1337-1338.	6.3	28
52	A Multi-Compartment Single and Multiple Dose Pharmacokinetic Comparison of Rectally Applied Tenofovir 1% Gel and Oral Tenofovir Disoproxil Fumarate. <i>PLoS ONE</i> , 2014, 9, e106196.	1.1	28
53	Heterosexual anal intercourse has the potential to cause a significant loss of power in vaginal microbicide effectiveness studies. <i>Sexually Transmitted Diseases</i> , 2010, 37, 361-4.	0.8	28
54	Safety and Pharmacokinetics of a Tenofovir Alafenamide Fumarate-Emtricitabine based Oral Antiretroviral Regimen for Prevention of HIV Acquisition in Women: A Randomized Controlled Trial. <i>EClinicalMedicine</i> , 2021, 36, 100893.	3.2	27

#	ARTICLE	IF	CITATIONS
55	Protection Against Rectal Chimeric Simian/Human Immunodeficiency Virus Transmission in Macaques by Rectal-Specific Gel Formulations of Maraviroc and Tenofovir. <i>Journal of Infectious Diseases</i> , 2015, 212, 1988-1995.	1.9	26
56	Youth-Specific Considerations in the Development of Preexposure Prophylaxis, Microbicide, and Vaccine Research Trials. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010, 54, S31-S42.	0.9	25
57	High levels of adherence to a rectal microbicide gel and to oral Pre-Exposure Prophylaxis (PrEP) achieved in MTN-017 among men who have sex with men (MSM) and transgender women. <i>PLoS ONE</i> , 2017, 12, e0181607.	1.1	25
58	Advances in the Development of Microbicides for the Prevention of HIV Infection. <i>Current Infectious Disease Reports</i> , 2010, 12, 56-62.	1.3	24
59	An Overview of Antiretroviral Pre-Exposure Prophylaxis of HIV Infection. <i>American Journal of Reproductive Immunology</i> , 2014, 71, 624-630.	1.2	23
60	Sensitive and reproducible quantitation of mucosal HIV-1 RNA and DNA viral burden in patients with detectable and undetectable plasma viral HIV-1 RNA using endoscopic biopsies. <i>Journal of Virological Methods</i> , 2001, 95, 65-79.	1.0	21
61	A Phase 1 Randomized, Blinded Comparison of the Pharmacokinetics and Colonic Distribution of Three Candidate Rectal Microbicide Formulations of Tenofovir 1% Gel with Simulated Unprotected Sex (CHARM-02). <i>AIDS Research and Human Retroviruses</i> , 2015, 31, 1098-1108.	0.5	20
62	Acceptability of Three Novel HIV Prevention Methods Among Young Male and Transgender Female Sex Workers in Puerto Rico. <i>AIDS and Behavior</i> , 2016, 20, 2192-2202.	1.4	20
63	Impact of Sex on the Pharmacokinetics and Pharmacodynamics of 1% Tenofovir Gel. <i>Clinical Infectious Diseases</i> , 2016, 62, 375-382.	2.9	20
64	Prevalence and determinants of anal human papillomavirus infection in men who have sex with men and transgender women. <i>International Journal of STD and AIDS</i> , 2019, 30, 154-162.	0.5	20
65	Phase 2a Safety, Pharmacokinetics, and Acceptability of Dapivirine Vaginal Rings in US Postmenopausal Women. <i>Clinical Infectious Diseases</i> , 2019, 68, 1144-1151.	2.9	19
66	Effective in vivo and ex vivo gene transfer to intestinal mucosa by VSV-G-pseudotyped lentiviral vectors. <i>BMC Gastroenterology</i> , 2010, 10, 44.	0.8	18
67	Nonreproducibility of Snap-Frozen Rectal Biopsies for Later Use in Ex Vivo Explant Infectivity Studies. <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 1509-1512.	0.5	18
68	Rectal-Specific Microbicide Applicator: Evaluation and Comparison with a Vaginal Applicator Used Rectally. <i>AIDS and Behavior</i> , 2014, 18, 1734-1745.	1.4	18
69	Rectal microbicide development. <i>Current Opinion in HIV and AIDS</i> , 2012, 7, 526-533.	1.5	17
70	The pharmacokinetics, pharmacodynamics, and mucosal responses to maraviroc-containing pre-exposure prophylaxis regimens in MSM. <i>Aids</i> , 2019, 33, 237-246.	1.0	17
71	Development of HIV-1 Rectal-Specific Microbicides and Colonic Tissue Evaluation. <i>PLoS ONE</i> , 2014, 9, e102585.	1.1	17
72	Adherence to Rectal Gel Use Among Mainly Ethnic Minority Young Men Who have Sex with Men During A 3-Month Placebo Gel Trial: Implications for Microbicide Research. <i>AIDS and Behavior</i> , 2014, 18, 1726-1733.	1.4	16

#	ARTICLE	IF	CITATIONS
73	Influence of Partner Type on Acceptability and Likelihood of Use of a Rectal Microbicide Among Young Men Who Have Sex With Men in the United States and Puerto Rico. <i>Journal of Sex Research</i> , 2016, 53, 633-641.	1.6	16
74	Preference of Oral Tenofovir Disoproxil Fumarate/Emtricitabine Versus Rectal Tenofovir Reduced-Glycerin 1% Gel Regimens for HIV Prevention Among Cisgender Men and Transgender Women Who Engage in Receptive Anal Intercourse with Men. <i>AIDS and Behavior</i> , 2017, 21, 3336-3345.	1.4	16
75	Modeling the potential impact of rectal microbicides to reduce HIV transmission in bathhouses. <i>Mathematical Biosciences and Engineering</i> , 2006, 3, 459-466.	1.0	16
76	Rectal Microbicide Development. <i>Current Topics in Microbiology and Immunology</i> , 2013, 383, 117-136.	0.7	15
77	How common and frequent is heterosexual anal intercourse among South Africans? A systematic review and meta-analysis. <i>Journal of the International AIDS Society</i> , 2017, 20, 21162.	1.2	15
78	Soluble Immune Mediators and Vaginal Bacteria Impact Innate Genital Mucosal Antimicrobial Activity in Young Women. <i>American Journal of Reproductive Immunology</i> , 2015, 74, 323-332.	1.2	14
79	Analytical Advances in the <i>Ex Vivo</i> Challenge Efficacy Assay. <i>AIDS Research and Human Retroviruses</i> , 2017, 33, 395-403.	0.5	14
80	Project Gel a Randomized Rectal Microbicide Safety and Acceptability Study in Young Men and Transgender Women. <i>PLoS ONE</i> , 2016, 11, e0158310.	1.1	14
81	Prevalence of Anal Human Papillomavirus Vaccine Types in the Bangkok Men Who Have Sex With Men Cohort Study. <i>Sexually Transmitted Diseases</i> , 2015, 42, 671-676.	0.8	13
82	A Pilot Study of the Prevalence of Anal Human Papillomavirus and Dysplasia in a Cohort of Patients With IBD. <i>Diseases of the Colon and Rectum</i> , 2017, 60, 1307-1313.	0.7	13
83	Mucosal Substance P Receptor Expression in HIV Infection and Inflammatory Bowel Disease. <i>NeuroImmunoModulation</i> , 1997, 4, 70-76.	0.9	12
84	Microbicides 2006 conference. <i>AIDS Research and Therapy</i> , 2006, 3, 25.	0.7	12
85	Mucosal gene therapy using a pseudotyped lentivirus vector encoding murine interleukin-10 (mIL-10) suppresses the development and relapse of experimental murine colitis. <i>BMC Gastroenterology</i> , 2014, 14, 68.	0.8	12
86	Exploring the Feasibility of Multi-Site Flow Cytometric Processing of Gut Associated Lymphoid Tissue with Centralized Data Analysis for Multi-Site Clinical Trials. <i>PLoS ONE</i> , 2015, 10, e0126454.	1.1	12
87	Increases in HIV Incidence Following Receptive Anal Intercourse Among Women: A Systematic Review and Meta-analysis. <i>AIDS and Behavior</i> , 2020, 24, 667-681.	1.4	12
88	ADVANCES IN MUCOSAL IMMUNOLOGY. <i>Gastroenterology Clinics of North America</i> , 1997, 26, 145-173.	1.0	11
89	Rectal 1% Tenofovir Gel Use Associates with Altered Epidermal Protein Expression. <i>AIDS Research and Human Retroviruses</i> , 2016, 32, 1005-1015.	0.5	11
90	To Use a Rectal Microbicide, First Insert the Applicator: Gel and Applicator Satisfaction Among Young Men Who Have Sex With Men. <i>AIDS Education and Prevention</i> , 2016, 28, 1-10.	0.6	11

#	ARTICLE	IF	CITATIONS
91	Lessons for Rectal Microbicide Development From an Acceptability Trial of a Placebo Gel Applied Prior to Receptive Anal Intercourse. <i>Archives of Sexual Behavior</i> , 2017, 46, 1101-1109.	1.2	11
92	Stability of 5P12-RANTES, A Candidate Rectal Microbicide, in Human Rectal Lavage. <i>AIDS Research and Human Retroviruses</i> , 2017, 33, 768-777.	0.5	11
93	Are participants concerned about privacy and security when using short message service to report product adherence in a rectal microbicide trial?. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2018, 25, 393-400.	2.2	11
94	Receptive anal sex contributes substantially to heterosexually acquired HIV infections among at-risk women in twenty US cities: Results from a modelling analysis. <i>American Journal of Reproductive Immunology</i> , 2020, 84, e13263.	1.2	11
95	Treatment with Commonly Used Antiretroviral Drugs Induces a Type I/III Interferon Signature in the Gut in the Absence of HIV Infection. <i>Cell Reports Medicine</i> , 2020, 1, 100096.	3.3	10
96	Higher colorectal tissue HIV infectivity in cisgender women compared with MSM before and during oral preexposure prophylaxis. <i>Aids</i> , 2021, 35, 1585-1595.	1.0	10
97	Cytokine gene transcription of human colonic intraepithelial lymphocytes costimulated with epithelial cells bearing HLA-DR and its inhibition by 5-aminosalicylic acid. <i>Journal of Clinical Immunology</i> , 1996, 16, 237-241.	2.0	9
98	Injectable and implantable antiretroviral strategies for HIV prevention. <i>Future Virology</i> , 2015, 10, 1163-1176.	0.9	9
99	Distinct Pharmacodynamic Activity of Rilpivirine in Ectocervical and Colonic Explant Tissue. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 2765-2770.	1.4	9
100	Brief Participant-Centered Convergence Interviews Integrate Self-Reports, Product Returns, and Pharmacokinetic Results to Improve Adherence Measurement in MTN-017. <i>AIDS and Behavior</i> , 2018, 22, 986-995.	1.4	9
101	Pharmacokinetics and Pharmacodynamics of Tenofovir Reduced-Glycerin 1% Gel in the Rectal and Vaginal Compartments in Women: A Cross-Compartmental Study With Directly Observed Dosing. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 78, 175-182.	0.9	9
102	Rectal microbicides. <i>Current Opinion in HIV and AIDS</i> , 2008, 3, 593-598.	1.5	8
103	The Molecular Characterization of Intestinal Explant HIV Infection Using Polymerase Chain Reaction-Based Techniques. <i>AIDS Research and Human Retroviruses</i> , 2015, 31, 981-991.	0.5	8
104	The Safety of Multiple Flexible Sigmoidoscopies with Mucosal Biopsies in Healthy Clinical Trial Participants. <i>AIDS Research and Human Retroviruses</i> , 2017, 33, 820-826.	0.5	8
105	Ranpirnase Reduces HIV-1 Infection and Associated Inflammatory Changes in a Human Colorectal Explant Model. <i>AIDS Research and Human Retroviruses</i> , 2018, 34, 838-848.	0.5	8
106	Hydroxyurea Does Not Enhance the Anti-HIV Activity of Low-Dose Tenofovir Disoproxil Fumarate. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2001, 28, 336-339.	0.9	7
107	Factors Supporting and Hindering Adherence to Rectal Microbicide Gel Use with Receptive Anal Intercourse in a Phase 2 Trial. <i>AIDS and Behavior</i> , 2018, 22, 388-401.	1.4	7
108	Immunological responsiveness of intestinal tissue explants and mucosal mononuclear cells to ex vivo stimulation. <i>Journal of Immunological Methods</i> , 2018, 463, 39-46.	0.6	7

#	ARTICLE	IF	CITATIONS
109	An Open-Label Pharmacokinetic and Pharmacodynamic Assessment of Tenofovir Gel and Oral Emtricitabine/Tenofovir Disoproxil Fumarate. <i>AIDS Research and Human Retroviruses</i> , 2022, 38, 279-287.	0.5	7
110	Use of a Novel Technology to Track Adherence to Product Use in a Microbicide Trial of Short Duration (MTN-007). <i>AIDS and Behavior</i> , 2013, 17, 3101-3107.	1.4	6
111	Tofacitinib inhibits inflammatory cytokines from ulcerative colitis and healthy mucosal explants and is associated with pSTAT1/3 reduction in T-cells. <i>American Journal of Physiology - Renal Physiology</i> , 2021, 320, G396-G410.	1.6	6
112	A Multiple Dose Phase 1 Assessment of Rilpivirine Long Acting in a Model of Preexposure Prophylaxis Against HIV. <i>AIDS Research and Human Retroviruses</i> , 2019, 35, 794-804.	0.5	5
113	The Use of Droplet Digital PCR to Quantify HIV-1 Replication in the Colorectal Explant Model. <i>AIDS Research and Human Retroviruses</i> , 2019, 35, 326-334.	0.5	5
114	A Randomized, Double Blind, Placebo-Controlled, Phase 1 Safety and Pharmacokinetic Study of Dapivirine Gel (0.05%) Administered Rectally to HIV-1 Seronegative Adults (MTN-026). <i>AIDS Research and Human Retroviruses</i> , 2021, , .	0.5	5
115	A Randomized, Open-Label, Crossover Phase 1 Safety and Pharmacokinetic Study of Oral Maraviroc and Maraviroc 1% Gel (the CHARM-03 Study). <i>AIDS Research and Human Retroviruses</i> , 2022, 38, 269-278.	0.5	5
116	Intestinal mucosal abnormality associated with human immunodeficiency virus infection. <i>European Journal of Gastroenterology and Hepatology</i> , 1994, 6, 813-820.	0.8	4
117	A Phase 1 Open Label Safety, Acceptability, Pharmacokinetic, and Pharmacodynamic Study of Intramuscular TMC278 LA (the MWRI-01 Study). <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A71-A71.	0.5	4
118	Variability of cytokine gene expression in intestinal tissue and the impact of normalization with the use of reference genes. <i>Cytokine</i> , 2015, 71, 81-88.	1.4	4
119	Comparative Assessment of Small and Large Intestine Biopsies for <i>Ex Vivo</i> HIV-1 Pathogenesis Studies. <i>AIDS Research and Human Retroviruses</i> , 2018, 34, 900-906.	0.5	4
120	A Pilot Study of the Immunologic, Virologic, and Pathologic Consequences of Intra-anal 5% Imiquimod in HIV-1 Infected Men With High-Grade Squamous Intraepithelial Lesions. <i>Diseases of the Colon and Rectum</i> , 2018, 61, 298-305.	0.7	4
121	Evaluation of the Safety, Acceptability, and Pharmacokinetic Profile of a Gel Formulation of OB-002 in Healthy Volunteers. <i>AIDS Research and Human Retroviruses</i> , 2021, 37, 453-460.	0.5	4
122	Brief Report: Dipyridamole Decreases Gut Mucosal Regulatory T-Cell Frequencies Among People With HIV on Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 85, 665-669.	0.9	4
123	The Motivations and Experiences of Young Women in a Microbicide Trial in the USA and Puerto Rico. <i>World Journal of AIDS</i> , 2013, 03, 179-186.	0.1	4
124	Acceptability of a Dapivirine/Placebo Gel Administered Rectally to HIV-1 Seronegative Adults (MTN-026). <i>AIDS and Behavior</i> , 2022, 26, 1333-1346.	1.4	4
125	Rectal Specific Gels Containing Maraviroc and/or Tenofovir Protect against Rectal SHIV Transmission in a Macaque Model. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A13-A14.	0.5	3
126	AIDS and intestinal disease. <i>Current Opinion in Gastroenterology</i> , 1997, 13, 18-23.	1.0	2

#	ARTICLE	IF	CITATIONS
127	Sex Matters: MTN-011 Phase 1 Study on the Impact of Sex on Tenofovir Gel Pharmacokinetics (PK) and Pharmacodynamics (PD). <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A38-A38.	0.5	1
128	Proteomics Based Methods for Toxicity Monitoring of Rectal Microbicides. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A229-A229.	0.5	1
129	Humic Acids (HA) Strongly Potentiate Anti-HIV Effects of AZT, Griffithsin, and Cyanovirin. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A204-A204.	0.5	1
130	Interactive Voice Response System (IVRS): Data Quality Considerations and Lessons Learned During a Microbicide Placebo Adherence Trial With Young Men Who Have Sex With Men. <i>Journal of Adolescent Health</i> , 2014, 54, S57-S58.	1.2	1
131	Microbicides. , 2009, , 85-106.		1
132	Intestinal mucosal CCR5 expression is down-regulated in HIV infection. <i>Gastroenterology</i> , 2003, 124, A155.	0.6	0
133	The IL-10/IL-12 axis and regulation of DC-SIGN expression in HIV-infected human gut mucosa. <i>Gastroenterology</i> , 2003, 124, A155-A156.	0.6	0
134	A Phase 1 Evaluation of the Rectal Safety, Acceptability, Pharmacokinetics, and Pharmacodynamics of Three Formulations of Tenofovir 1% Gel. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A283-A284.	0.5	0
135	The Research Registry: A Valuable Strategy for Longitudinal Success in HIV Prevention Research Recruitment. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A173-A173.	0.5	0
136	Performance of the Wisebag [®] for Monitoring Daily Rectal Gel Application in Two Urban Cities in the United States. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A167-A168.	0.5	0
137	Preventing Drug Resistant HIV Infection in Colonic Tissue using Tenofovir and Maraviroc Combination Topical Rectal Gels. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A261-A262.	0.5	0
138	An ex vivo Model to Determine Stat Protein Phosphorylation in Human Colorectal Mononuclear Mucosal Cells Obtained From Biopsies. <i>Gastroenterology</i> , 2017, 152, S965-S966.	0.6	0